Coronavirus

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of.

Everything you need to know about the covid-19 IP waiver negotiations
The Medicines Patent Pool – not C-TAP – is the missed opportunity for covid vaccines
28 May 2021

The Medicines Patent Pool – not C-TAP – is the missed opportunity for covid vaccines

A scheme premised on a rejection of the legitimacy of IP during a pandemic was never going to get the buy-in necessary to make it work

The USPTO Director choice may effectively come down to Chris Coons
25 May 2021

The USPTO Director choice may effectively come down to Chris Coons

White House backing for the covid vaccine IP waiver puts the pro-patent Delaware senator in a powerful position to decide who gets the job

Latest

View all
21 May 2021

As the pandemic bit, Schaeffler Group, Sanofi and Abbott led the way with US patent abandonments in 2020

Exclusive IAM analysis reveals how leading businesses in seven industries handled renewals at the height of the covid-19 crisis Read more

18 May 2021

India resists calls to use existing compulsory licensing powers for covid drugs

Despite advocacy of TRIPS waiver, the country’s government has expressed reluctance to bypass patent rights Read more

17 May 2021

Iancu slams Biden Administration’s backing for “dangerous” covid vaccine IP waiver

“Once you have taken this genie out of the bottle, it will be very hard to put it back in again,” says former USPTO head Read more

11 May 2021

Brazilian Supreme Court set to decide whether tens of thousands of patents live or die

Up to 30,000 individual grants are at risk as the country’s highest court decides whether to retroactively apply a landmark ruling it handed down last week Read more

News

View all
8 May 2021

Biden’s backing for the covid vaccine IP waiver should concern all rights owners

This week’s unprecedented move raises a series of worrying questions and puts in doubt the administration’s commitment to fostering innovative activity Read more

26 Apr 2021

Get smarter about covid patents or pay the price

On World IP Day it's time to get a few things straight about where the real problems in getting jabs to those who need them really lie Read more

2 Mar 2021

Negotiating patent licensing agreements during a pandemic

Co-published - Although some major deals in the semiconductor space have been concluded over the last year, respondents to a survey on virtual negotiations see major difficulties in online discussions Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

Analysis

View all
6 May 2021

Biden backs covid-19 IP waiver in historic US policy shift

Landmark move suggests realignment in America’s domestic and international healthcare IP stance Read more

4 May 2021

Brazilian Senate passes compulsory covid-19 know-how licensing bill

Vaccine owners may be forced to hand over trade secrets or have their patents cancelled under legislation endorsed by the upper house of the country’s Congress Read more

20 Apr 2021

TRIPS covid vaccine IP waiver proposal fails to address crucial questions

President Biden and other leaders are coming under pressure to agree a suspension of IP rights, but a key point has been missed Read more

13 Apr 2021

Brazil suspends drug patent extensions and reschedules key Supreme Court hearing for tomorrow

Long-running constitutional challenge putting 40% of patents at-risk set to be resolved, but further delays are possible Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

Find an expert